CureVac - Hauptforum Forum: Community User: NeulingImDAX

Jonathan7 today 12:38 pm 0 Studies of the German vaccine, Curevac, in Argentina, showed an efficacy of 95% where the research headquarters is located in Berazategui and it is expected to be approved this month. The results of the formula used by the biopharmaceutical company confirmed the 95% efficacy of the vaccine against the SARS-CoV-2 virus, 28 days after the first dose and seven days after the second. They report that the Curevac vaccine appears to be "very well positioned" and was developed with the support of the German government and the European Community, and successfully completed phase 1 and phase 2 trials. Now the vaccine is in phase 3 in different countries around the world. For example, in Argentina, the Buenos Aires Ministry of Health opened registration to participate in clinical trials on March 18, under the general coordination of the Evita Pueblo hospital in Berazategui. Juan Marini, executive director of the hospital, indicated that “the protocol has a 13-month follow-up, although it may continue until two years. We assume that in the first days of June the study will be approved in Europe. From there, it will be easy for the ANMAT to approve it ”.

Jonathan, könntest du mal unter deinen Beiträgen eine Quelle angeben?

Regarding the symptoms of the vaccine, the director explained that "there were some minor manifestations such as low-grade fever, muscle aches, the usual of a vaccine." In addition, he highlighted that severe allergic reactions were not recorded either. " The study had opened the registration for 9 thousand volunteers in different parts of the Province, a center in Rosario and another in CABA. Among them, some received both doses of the vaccine to be tested, while others were inoculated with a placebo. In addition, not only the German company is carrying out the studies in Berazategui, but they are also working in two public hospitals in the province of Buenos Aires: the Vicente López y Planes de General Rodríguez Hospital, and the Ramón Carrillo de Tres de Febrero .

Studies of the German vaccine , Curevac , in Argentina, showed an efficacy of 95% where the research headquarters is located in Berazategui and it is expected to be approved this month. The results of the formula used by the biopharmaceutical company confirmed the 95% efficacy of the vaccine against the SARS-CoV-2 virus, 28 days after the first dose and seven days after the second. They report that the Curevac vaccine appears to be "very well positioned" and was developed with the support of the German government and the European Community, and successfully completed phase 1 and phase 2 trials. Now the vaccine is in phase 3 in different countries around the world. For example, in Argentina, the Buenos Aires Ministry of Health opened registration to participate in clinical trials on March 18, under the general coordination of the Evita Pueblo hospital in Berazategui. Juan Marini, executive director of the hospital, indicated that “the protocol has a 13-month follow-up, although it may continue until two years. We assume that in the first days of June the study will be approved in Europe. From there, it will be easy for the ANMAT to approve it ”.

@Newe : interessant 🧐

@BreitF habe das gelesen! Ja - sehr interessant - von der medizinischen Kompetenz des Schreiberlings bin ich beeindruckt

ANMAT have asked for the vaccine- it showed 95% in effficacy in 3 trials Argentina- I am not saying that is right or wrong but on June 4 ANMAT requested Curevac supply to them its published as well

@M610 die Kommunikation von gestern ! Hatte die Frage aufgeworfen, wie es mit der Erstellung vontheoretischen Nachweisen aussieht beDonald 23:18 von Ruudi ::: Das ist offenbar tatsächlich der Fall. Ich hatte vor rd. 2. Wochen einmal auf das Design der von der UK Gesundheitsbehörde PHE bezahlten Studie aufmerksam gemacht. Danach wurden die Zahlen der in UK massgeblich verimpften Vakzine (AZ und BioNTech) mittels mathematischer Verfahren geschätzt. Dies wurde von zahlreichen britischen Experten heftig kritisiert. Der entsprechende Link bei PHE wurde offenbar entfernt. Aber ich glaube das hier ist die Studie (Auftraggeber S.1; Design ab S.4 ff.). https://khub.net/documents/135939561/405676950/Increased Household Transmission of COVID-19 Cases - national case study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa Vgl. dazu auch die Einschätzung der renommierten und anerkannten Fachpublikation The Lancet: https://www.aerzteblatt.de/nachrichten/124417/Grossbritannien-Delta-Variante-von-SARS-CoV-2-breitet-sich-bei-offenbar-verminderter-Impfstoffwirkung-weiter-aus bzw. direkt https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01290-3/fulltext Dazu passt der folgende Spruch, der gerüchteweise Winston Churchill zugeschrieben wird: „Ich glaube nur der Statistik, die ich selbst gefälscht habe …“

The below is 100% wrong that Artikle posts with Nature- the facts are clear. DELTA in the UK is spreading- the deaths are clear in people already vaccinated with pfizer- 4 people died who had the vaccine- that is 4 out of 21 people. You can not cherry pick Other issue here is the vested interests and I have just laid into a friend in NL- we have been friend for 20 years and I said cut the crap- Pfizer pusaded you to drop out of a trial when you second dose was due. What is lost here is the vested interests and how they promote them. Propublica as been advised to stop publishing the details of Doctors in the USA who get $500,000 per year from Pfizer - some get less- A doctor named TOPOL who promotes Pfizer and others as tried to stop Propublica produing the payment he had in Janaury.. We do not know the full details on the vaccine data from Curevac- and I am not going to mislead anyone at all- but on June 4th ANMAT asked Curevac can they supply and they did so because the effficacy in 3 trials came out at 95%, but that is part of a trial - when added into all data - it may be the efficacy is lower like initial reports but ANMAT want the vacccine Article14 12:09 pm today 0 Just for comparison, Biontech works at Delta 87.9 percent (B.1.617.2 source: "Nature")

Hier ist z.B. ein guter Artikel darüber: https://www.deutsche-apotheker-zeitung.de/news/artikel/2021/06/18/geringere-immunantwort-gegen-delta-variante-von-sars-cov-2

Artikel14 kannst du einmal nen link hier reinstellen bitte? Würde das gerne gleich einmal lesen (falls zur Hand, ansonsten suche ich später selber)

Nur mal zum Vergleich Biontech wirkt bei Delta 87,9 Prozent (B.1.617.2 Quelle: "Nature")